BORTEK Bor Teknolojileri ve Mekatronik San. Tic. A.Ş.


KnfleX® Solution for Osteoarthritis(OA) treatment

Osteoarthritis (OA) is a long-term chronic disease characterized by a deterioration of cartilage in the joints. With the progression of OA, bones begin to rub against each other creating stiffness, pain, and impaired movement. OA prevents large numbers of people from being fully active members of society.
OA is the most common musculoskeletal disorder impacting the life quality of around 57 million Europeans and approximately 355 million others affected worldwide. The global OA treatment market is expected to register a CAGR of 4.8% from 2017 to 2025.

Traditionally, the pharmacological management of OA has focused on therapies that may improve or control symptoms. Such approaches include analgesics, anti-inflammatory agents, intra-articular corticosteroids or hyaluronic acid, glucosamine sulphate, and chondroitin sulphate. However, these are not cures and do not stop the progression of OA.

There is an unmet medical need for OA therapies that benefit pain and function and mitigate the structural damage caused by OA. For this purpose, a Draft Guidance on OA was released by the FDA in August, 2018 . The ultimate goal of treatments related to inhibition of structural damage or targeting the underlying pathophysiology associated with OA is to avoid or significantly delay the complications of joint failure and the need for joint replacement, and also to reduce the deterioration of function and worsening of pain.

BORTEK® has developed an innovative KnfleX® cream for improving the health of OA sufferers. Lubricating the OA area permanently with a super solid lubricant is a first in the world and it contributes to an easy movement of knee joints with damaged cartilage caused by OA. Therefore, it relieves pain, halts the progress of OA and improves the life quality. It is more efficacious compared to other remedies available today. BORTEK®’s value proposition is that KnfleX® relieves pain, improves movement and stops the progress of OA.

BORTEK is looking for investors for its patented product that relieves and halts progress of osteoarthritis (OA), which affects 355 million people worldwide.